Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1-10 BMs). The median SRS treatment volume was 0.79 cm3 (range: 0.003-38.18 cm3), and the median SRS prescription dose was 20 Gy (range: 8-24 Gy). The median survival after SRS for BMs was 14 months (range: 3-58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143-11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689-0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.

Department of Functional Neurosurgery and Radiosurgery Ruber International Hospital Madrid Spain

Department of Neurological Surgery Centre de recherche du CHUS Université de Sherbrooke Sherbrooke Canada

Department of Neurological Surgery Na Homolce Hospital Prague Czech Republic

Department of Neurosurgery and University of Southern California Los Angeles California USA

Department of Neurosurgery Neurological Institute Taipei Veteran General Hospital Taipei Taiwan

Department of Neurosurgery NYU Langone Health New York University New York New York USA

Department of Neurosurgery University of Pennsylvania Philadelphia Pennsylvania USA

Department of Neurosurgery University of Virginia Charlottesville Virginia USA

Department of Radiation Oncology and NYU Langone Health New York University New York New York USA

Department of Radiation Oncology Mayo Clinic Jacksonville Florida USA

Department of Radiation Oncology University of Southern California Los Angeles California USA

Division of Radiation Oncology Department of Oncology University of Alberta Edmonton Canada

000      

00000naa a2200000 a 4500

001      

bmc22012343

003      

CZ-PrNML

005      

20220506130211.0

007      

ta

008      

220425s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1089/thy.2020.0947 $2 doi

035    __

$a (PubMed)33978475

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Bunevicius, Adomas $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA

245    10

$a Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study / $c A. Bunevicius, S. Fribance, S. Pikis, JYK. Lee, LY. Buch, M. Moran, AI. Yang, K. Bernstein, D. Mathieu, R. Perron, R. Liscak, G. Simonova, S. Patel, DM. Trifiletti, R. Martínez Álvarez, N. Martínez Moreno, CC. Lee, HC. Yang, BA. Strickland, G. Zada, EL. Chang, D. Kondziolka, J. Sheehan

520    9_

$a Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1-10 BMs). The median SRS treatment volume was 0.79 cm3 (range: 0.003-38.18 cm3), and the median SRS prescription dose was 20 Gy (range: 8-24 Gy). The median survival after SRS for BMs was 14 months (range: 3-58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143-11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689-0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.

650    _2

$a folikulární adenokarcinom $x sekundární $x chirurgie $7 D018263

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a nádory mozku $x sekundární $x chirurgie $7 D001932

650    _2

$a papilární karcinom $x sekundární $x chirurgie $7 D002291

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a Karnofského skóre $7 D017567

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a doba přežití bez progrese choroby $7 D000077982

650    _2

$a radiochirurgie $x škodlivé účinky $x metody $7 D016634

650    _2

$a analýza přežití $7 D016019

650    _2

$a nádory štítné žlázy $x patologie $7 D013964

650    _2

$a výsledek terapie $7 D016896

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

700    1_

$a Fribance, Sarah $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA

700    1_

$a Pikis, Stylianos $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA

700    1_

$a Lee, John Y K $u Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA

700    1_

$a Buch, Love Y $u Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA

700    1_

$a Moran, Michael $u Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA

700    1_

$a Yang, Andrew I $u Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA

700    1_

$a Bernstein, Kenneth $u Department of Radiation Oncology and NYU Langone Health, New York University, New York, New York, USA

700    1_

$a Mathieu, David $u Department of Neurological Surgery, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Canada

700    1_

$a Perron, Rémi $u Department of Neurological Surgery, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Canada

700    1_

$a Liscak, Roman $u Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic

700    1_

$a Simonova, Gabriela $u Department of Neurological Surgery, Na Homolce Hospital, Prague, Czech Republic

700    1_

$a Patel, Samir $u Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Canada

700    1_

$a Trifiletti, Daniel M $u Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA

700    1_

$a Martínez Álvarez, Roberto $u Department of Functional Neurosurgery and Radiosurgery, Ruber International Hospital, Madrid, Spain

700    1_

$a Martínez Moreno, Nuria $u Department of Functional Neurosurgery and Radiosurgery, Ruber International Hospital, Madrid, Spain

700    1_

$a Lee, Cheng-Chia $u Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan

700    1_

$a Yang, Huai-Che $u Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan

700    1_

$a Strickland, Ben A $u Department of Neurosurgery and University of Southern California, Los Angeles, California, USA

700    1_

$a Zada, Gabriel $u Department of Neurosurgery and University of Southern California, Los Angeles, California, USA

700    1_

$a Chang, Eric L $u Department of Radiation Oncology, University of Southern California, Los Angeles, California, USA

700    1_

$a Kondziolka, Douglas $u Department of Neurosurgery, NYU Langone Health, New York University, New York, New York, USA

700    1_

$a Sheehan, Jason $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA

773    0_

$w MED00004519 $t Thyroid : official journal of the American Thyroid Association $x 1557-9077 $g Roč. 31, č. 8 (2021), s. 1244-1252

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33978475 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130203 $b ABA008

999    __

$a ok $b bmc $g 1789787 $s 1163544

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 31 $c 8 $d 1244-1252 $e 20210511 $i 1557-9077 $m Thyroid $n Thyroid $x MED00004519

LZP    __

$a Pubmed-20220425